Írland - enska - HPRA (Health Products Regulatory Authority)

hospira uk limited - gemcitabine hydrochloride - concentrate for solution for infusion - 38 base mg/ml - gemcitabine

Írland - enska - HPRA (Health Products Regulatory Authority)

fresenius kabi oncology plc - gemcitabine hydrochloride - concentrate for solution for infusion - 40 milligram(s)/millilitre - pyrimidine analogues; gemcitabine

Írland - enska - HPRA (Health Products Regulatory Authority)

fresenius kabi oncology plc - gemcitabine hydrochloride - concentrate for solution for infusion - 38 milligram(s)/millilitre - pyrimidine analogues; gemcitabine

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

hetero australia pty ltd - gemcitabine hydrochloride, quantity: 1138 mg - injection, powder for - excipient ingredients: mannitol; sodium acetate trihydrate; sodium hydroxide - gemcitabine is indicated for treatment of patients with locally advanced or metastatic non- small cell lung cancer.,gemcitabine is indicated for treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas. gemcitabine is also indicated for patients with 5-fu refractory pancreatic cancer.,gemcitabine, alone or in combination with cisplatin, is indicated for treatment of patients with bladder cancer.,gemcitabine, in combination with paclitaxel, is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated.,gemcitabine, in combination with carboplatin, is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma, who have relapsed > 6 months following platinum? based therapy

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

hetero australia pty ltd - gemcitabine hydrochloride, quantity: 228 mg - injection, powder for - excipient ingredients: sodium hydroxide; mannitol; sodium acetate trihydrate - gemcitabine is indicated for treatment of patients with locally advanced or metastatic non- small cell lung cancer.,gemcitabine is indicated for treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas. gemcitabine is also indicated for patients with 5-fu refractory pancreatic cancer.,gemcitabine, alone or in combination with cisplatin, is indicated for treatment of patients with bladder cancer.,gemcitabine, in combination with paclitaxel, is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated.,gemcitabine, in combination with carboplatin, is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma, who have relapsed > 6 months following platinum? based therapy

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

medtas pty ltd - gemcitabine hydrochloride, quantity: 228 mg - injection, powder for - excipient ingredients: sodium acetate trihydrate; mannitol; sodium hydroxide - gemcitabine is indicated for treatment of patients with locally advanced or metastatic non- small cell lung cancer.,gemcitabine is indicated for treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas. gemcitabine is also indicated for patients with 5-fu refractory pancreatic cancer.,gemcitabine, alone or in combination with cisplatin, is indicated for treatment of patients with bladder cancer.,gemcitabine, in combination with paclitaxel, is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated.,gemcitabine, in combination with carboplatin, is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma, who have relapsed > 6 months following platinum? based therapy

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

medtas pty ltd - gemcitabine hydrochloride, quantity: 1138 mg - injection, powder for - excipient ingredients: mannitol; sodium acetate trihydrate; sodium hydroxide - gemcitabine is indicated for treatment of patients with locally advanced or metastatic non- small cell lung cancer.,gemcitabine is indicated for treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas. gemcitabine is also indicated for patients with 5-fu refractory pancreatic cancer.,gemcitabine, alone or in combination with cisplatin, is indicated for treatment of patients with bladder cancer.,gemcitabine, in combination with paclitaxel, is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated.,gemcitabine, in combination with carboplatin, is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma, who have relapsed > 6 months following platinum? based therapy

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

medtas pty ltd - gemcitabine hydrochloride, quantity: 1138 mg - injection, powder for - excipient ingredients: sodium hydroxide; mannitol; sodium acetate trihydrate - gemcitabine is indicated for treatment of patients with locally advanced or metastatic non- small cell lung cancer.,gemcitabine is indicated for treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas. gemcitabine is also indicated for patients with 5-fu refractory pancreatic cancer.,gemcitabine, alone or in combination with cisplatin, is indicated for treatment of patients with bladder cancer.,gemcitabine, in combination with paclitaxel, is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated.,gemcitabine, in combination with carboplatin, is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma, who have relapsed > 6 months following platinum? based therapy

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

medtas pty ltd - gemcitabine hydrochloride, quantity: 228 mg - injection, powder for - excipient ingredients: sodium acetate trihydrate; mannitol; sodium hydroxide - gemcitabine is indicated for treatment of patients with locally advanced or metastatic non- small cell lung cancer.,gemcitabine is indicated for treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas. gemcitabine is also indicated for patients with 5-fu refractory pancreatic cancer.,gemcitabine, alone or in combination with cisplatin, is indicated for treatment of patients with bladder cancer.,gemcitabine, in combination with paclitaxel, is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated.,gemcitabine, in combination with carboplatin, is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma, who have relapsed > 6 months following platinum? based therapy

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - gemcitabine hydrochloride, quantity: 1140 mg (equivalent: gemcitabine, qty 1000 mg) - injection, powder for - excipient ingredients: sodium acetate trihydrate; sodium hydroxide; mannitol - gemcitabine ebewe is indicated for treatment of patients with: . - locally advanced or metastatic non-small cell lung cancer (nsclc) . - locally advanced or metastatic adenocarcinoma of the pancreas. - fluorouracil refractory pancreatic cancer. - (alone or in combination with cisplatin) bladder cancer. . - (in combination with paclitaxel) unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. . - (in combination with carboplatin) recurrent epithelial ovarian carcinoma, who have relapsed > 6 months following platinum-based therapy.